Alcon Research

alcon.com

Total trials

622

Active

17

Phase 3

108

Total enrollment

121,938

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 7 of 7 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Vehicle14
Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free2
Aflibercept2
AR-14034 SR implant lower dose1
AR-14034 SR implant higher dose1
AR-14034 SR implant1
Sham procedure1

Next readouts

  • 2027-02
  • 2027-03
  • 2027-05

Top conditions

  • Ocular Hypertension98
  • Cataract72
  • Myopia61
  • Dry Eye50
  • Refractive Errors46
  • Refractive Error44
  • Glaucoma38
  • Astigmatism35

Frequently asked questions about Alcon Research

How many clinical trials does Alcon Research have on ClinicalTrials.gov?
Alcon Research is listed as the lead sponsor on 622 clinical trials in ClinicalTrials.gov, 17 of which are currently active (recruiting, enrolling, or ongoing).
How many of Alcon Research's trials are in Phase 3?
108 of Alcon Research's trials are in Phase 3, spread across 7 active drug programs.
What therapeutic areas does Alcon Research focus on?
Alcon Research's most-studied conditions on ClinicalTrials.gov are Ocular Hypertension, Cataract, Myopia, Dry Eye, Refractive Errors.
When are Alcon Research's next clinical trial readouts?
Alcon Research has 3 upcoming primary-completion readouts tracked here; the soonest is “An Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness”, expected around 2027-02.